Elevated Plasma Levels of the Pituitary Hormone Cthrc1 in Individuals with Red Hair but Not in Patients with Solid Tumors

Christine W. Duarte, J. Patrizia Stohn, Qiaozeng Wang, Ivette F. Emery, Andrew Prueser, Volkhard Lindner*

Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine, United States of America

Abstract

Background: An increasing number of studies report that Cthrc1 is expressed in various cancer cells. The present study sought to identify which cells in tumors and remodeling tissues express Cthrc1 and investigate the range of circulating human Cthrc1 levels in health and disease.

Methodology/Principle Findings: Highly specific monoclonal antibodies were generated to detect Cthrc1 by ELISA in plasma and in tissues by immunohistochemistry. In human colon, gastric, breast, endometrial, pancreatic, kidney, lung and skin cancer, Cthrc1 was expressed by activated stromal cells and not the cancer cells themselves. Similarly, conditions evoking tissue remodeling, such as wound repair or angiotensin II-mediated hypertension, induced Cthrc1 expression in interstitial and adventitial fibroblasts and perivascular stromal cells. Levels of Cthrc1 in plasma from healthy subjects were near the lower detection limit except for individuals with red hair, who had up to several hundred fold higher levels. Elevated Cthrc1 was also found in patients with diabetes, inflammatory conditions, and infections, but not solid tumors. Transgenic mouse studies suggested that Cthrc1 expression by stromal cells does not contribute to circulating levels. In human pituitaries, Cthrc1 was expressed in the anterior and intermediate lobes with unencapsulated Cthrc1 accumulations typically surrounded by chromophobe cells.

Conclusions: We identify Cthrc1 as a marker for activated stromal cells. Cthrc1 is a pituitary hormone with significantly elevated levels in subjects carrying variant alleles of the melanocortin-1 receptor as well as in patients with inflammatory conditions.

Citation: Duarte CW, Stohn JP, Wang Q, Emery IF, Prueser A, et al. (2014) Elevated Plasma Levels of the Pituitary Hormone Cthrc1 in Individuals with Red Hair but Not in Patients with Solid Tumors. PLoS ONE 9(6): e100449. doi:10.1371/journal.pone.0100449

Editor: Paul Proost, University of Leuven, Rega Institute, Belgium

Received March 26, 2014; Accepted May 23, 2014; Published June 19, 2014

Copyright: © 2014 Duarte et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction.

Funding: This study was supported in part by National Institutes of Health grants HL69182 (J.L.) and P20 RR15555 from the National Center for Research Resources. The Histopathology Core Facility is supported by P20RR018789/20GM103465 (D. Wojchowski, PI) and P30RR030927/30GM103392 (R. Friesel, PI). The Mouse Transgenic and Imaging Core is supported by P30RR030927/30GM103392 (R. Friesel, PI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Antibody reagents used here are made available upon request.

* Email: lindnv@mmc.org

Introduction

We discovered collagen triple helix repeat containing 1 (Cthrc1) in a screen for novel sequences induced in arteries upon balloon catheter injury, where it was prominently induced in activated adventitial fibroblasts [1]. The response to this injury induces smooth muscle cell proliferation with intimal thickening and constrictive remodeling with reduction in lumen size and fibrosis of the adventitia. Since our discovery, Cthrc1 has frequently been identified as a gene upregulated in tumors based on microarray-based screening approaches [2]. Among the cancer cells reported to express Cthrc1 are melanomas [2,3], hepatocellular carcinoma [4], oral cancer [5], breast ductal carcinoma [6,7], pancreatic cancer [8], colorectal cancer [9,10], gastric cancer [11], and dermatofibrosarcoma protubers [12]. A recent study by Spector et al. [13] reported expression of Cthrc1 in myofibroblasts in muscular dystrophies. Many of the studies reporting Cthrc1 overexpression in cancers relied on microarray expression data and insufficiently characterized antibodies. We previously generated Cthrc1-specific monoclonal antibodies suitable for immunohistochemistry and validated them extensively using tissues from Cthrc1 transgenic mice and Cthrc1 null mice [14]. In the adult, we found expression of Cthrc1 was restricted to the brain, pituitary gland and some osteocytes [14] but expression in parenchymal cells was not detectable. The development of hepatic steatosis in Cthrc1 null mice in the absence of any detectable Cthrc1 expression in the liver led to our discovery that Cthrc1 is a hormone with pituitary and remodeling bone as likely sources contributing to circulating levels.

The present study built on our previous findings of circulating Cthrc1 and sought to investigate the levels of circulating Cthrc1 in healthy human subjects. In addition, approximately 1300 plasma samples from random patients were evaluated for Cthrc1 levels to
determine whether Cthrc1 is a biomarker for certain diseases. Furthermore, we used immunohistochemistry performed with rabbit monoclonal antibodies to localize Cthrc1 in various human cancers previously reported to overexpress Cthrc1. To address the question whether overexpression of Cthrc1 in stromal cells leads to elevated circulating levels of Cthrc1, we used a genetic approach with transgenic overexpression of Cthrc1 under the control of the Pdgfrb promoter.

Materials and Methods

Ethics Statement

All protocols involving animals were approved by the Institutional Animal Care and Use Committee of the Maine Medical Center (protocol number 1204) and were in compliance with all applicable regulations and guidelines including the National Institutes of Health Guide for Care and Use of Laboratory Animals. Human plasma samples were obtained under a protocol approved by the Institutional Review Board (IRB) of Maine Medical Center (protocol number 3657). Written consent was obtained from human subjects participating in this study. The IRB had approved the Informed Consent Form (ICF) and the procedure used to consent participants for the blood draw. After consenting, the participants were provided with a signed copy of the ICF. The original signed copy of the ICF is kept by the investigators in a secure place.

Transgenic mice and mouse tissues

Cre-inducible transgenic mice expressing human or rat Cthrc1, Tg(CagGfp-hCthrc1)78 and Tg(CagGfp-rCthrc1)78, were generated in the same manner as previously described for the myc-tagged rat Cthrc1 expressing strain Tg(CagGfp-Cthrc1myc)114Vli [15]. The coding region of human or rat Cthrc1 cDNA (Image clone 4586039, GenBank accession number BC014245) was cloned into the CagGfp vector as described [15] without addition of a tag. These mice were bred with previously described Tg(Pdgfrb-Cre)33Vli, were generated by the Institutional Animal Care and Use Committee of the Maine Medical Center (protocol number 3657). Written consent was obtained from human subjects participating in this study. The IRB had approved the Informed Consent Form (ICF) and the procedure used to consent participants for the blood draw. After consenting, the participants were provided with a signed copy of the ICF. The original signed copy of the ICF is kept by the investigators in a secure place.

Paraffin-embedded, formalin-fixed tissue blocks were prepared from pancreatic ductal adenocarcinoma (kindly provided by Dr. Howard Crawford, Mayo Clinic, Jacksonville, FL), testicular germ cell tumor, skin wounds, ischemic muscle tissue, anti-collagen antibody-induced arthritis joints [16], and hearts and arteries from wildtype and Cthrc1 null mice mice infused with angiotensin II for 7 days (500 ng/kg/min via osmotic minipump) [14].

Human plasma samples and paraffin-embedded tissue blocks

Samples were obtained from healthy adult male and female volunteers after obtaining informed consent. In collaboration with a primary care facility 792 plasma samples with EDTA as anticoagulant were obtained from patients visiting their primary care physicians. In addition, Maine Medical Center’s BioBank, a core facility of the institution, provided us with 505 plasma samples with lithium heparin as anticoagulant from hospitalized patients. All plasma samples would have otherwise been discarded. Plasma was processed and frozen within 6 hours of the blood draw for the outpatient samples and within 24 hours for the inpatient samples. After plasma isolation all samples were stored at −70°C until analysis.

Maine Medical Center’s BioBank also provided us with de-identified formalin-fixed, paraffin-embedded tissue blocks of various types of cancers that were reported to frequently overexpress Cthrc1 [2]. These included melanomas (n = 10), breast cancer (n = 10), colon cancer (n = 10), gastric cancer (n = 10), pancreatic cancer (n = 10), lung cancer (n = 5) and uterine cancer (n = 5). Human pituitary glands were obtained as autopsy specimens and the average ischemia time until fixation for those was 25 hours.

Monoclonal antibody and ELISA development

BALB/c and Cthrc1 null mice on the C57BL/6 [14] background were immunized with synthetic peptides corresponding to the N terminus of human and murine Cthrc1 (SENPKVKQKAQLRQRE and SENPKVKQKALRQRE) coupled to keyhole limpet hemocyanin as well as recombinant rat Cthrc1 with C terminal 8xHis expressed in E.coli. Using the services of Maine Biotechnology Services (Portland, ME), hybridomas were generated. Hybridoma supernatants were screened by indirect ELISA against human and rat Cthrc1 expressed in CHO-K1 cells. In addition, the supernatants were also screened by indirect ELISA against the N terminal peptides conjugated to bovine serum albumin (BSA) as well as by immunohistology of rat and human Cthrc1. All monoclonal antibodies referenced here are made available through www.mmcri.org/antibody. They detected a double band of approximately 30 kDa and 32 kDa on immunoblots of lysates and conditioned media of Cthrc1 adenovirus transduced CHO-K1 cells run under reducing conditions (Figure 1). Mass-spectrometry identified the upper band as Cthrc1 with the signal peptide still present and the lower band as Cthrc1 with the signal peptide cleaved (data not shown).

Monoclonal antibody 10G07 is specific for the N terminus of human Cthrc1 and does not react with rat or murine Cthrc1. Clones 02F06, 08G09, and 16B04 are specific for the N terminus of rat/mouse Cthrc1 and do not react with human Cthrc1 (not shown). Clone 13E09 recognizes an epitope located within the N terminal half of the molecular of both human and rodent Cthrc1 (not shown).

Clone 13E09 is suitable as a capturing antibody in a sandwich ELISA and biotinylated 10G07 or 08G09 (OneQuant Sulfo-NHS-
LC Biotin, G-Biosciences) were used as detection antibodies for human and rodent Cthrc1, respectively. It is important to note that none of the monoclonal antibodies generated recognized C terminally modified Cthrc1 by ELISA, even though their epitopes mapped to the N terminal half of the molecule. This included Cthrc1 with C terminal myc tag, myc/6xHis tag, 8xHis tag, or Cthrc1 with deletion of the C terminal lysine (K) residue.

**Figure 2. Immunolocalization of Cthrc1 in various remodeling mouse tissues.** Immunohistochemistry was performed using rabbit monoclonal antibody Vli-55. (A) In response to angiotensin II, Cthrc1 is induced in interstitial myocardial cells of wildtype mice, but no expression is detected in similarly treated Cthrc1 null mice (B). (C) Angiotensin II-induced Cthrc1 in outer mural cells of the renal artery of wildtype mice (arrows) but not Cthrc1 null mice (D). (E) A skin incisional wound with Cthrc1 localization in activated dermal cells but not in the epidermis (e). (F) Ischemic muscle injury led to Cthrc1 protein expression in interstitial cells but not myocytes (m). (G) An arthritic joint with Cthrc1 in activated synovial fibroblasts (sf) but not in chondrocytes (c) is shown. (H) Remodeling tumor vessels of a germ cell tumor reveal Cthrc1 in outer mural cells (arrows), and (I) pancreatic ductal cancer shows Cthrc1 in cells of the surrounding stroma (s) but not in the tumor cells (t). Cthrc1 immunoreactivity in brown with hematoxylin counterstain. Original magnification 100x (C), 200x (B, D, E, G, I), and 400x (A, F, H).

doi:10.1371/journal.pone.0100449.g002

**Figure 3. Cthrc1 localizes to tumor stroma.** Immunolocalization of Cthrc1 was performed in various human cancers to determine protein levels in stromal cells (S) and tumor cells (T). (A) Melanoma biopsies showed few Cthrc1-positive stromal cells surrounding the tumor (red stain, arrows). (B) Endometrial cancer had abundant Cthrc1 positive stroma adjacent to necrotic tumor area. (C) The endometrial cancer was stained with an irrelevant rabbit monoclonal antibody to ensure specificity. Tumor stroma from (D) breast ductal carcinoma, (E) colon adenocarcinoma, (F) pancreatic adenocarcinoma, and (G, H) lung carcinoma had abundant Cthrc1 protein localization surrounding the tumor cells. (I) Some adipocytes adjacent to the tumor had Cthrc1 expression (arrows). Cthrc1 immunoreactivity in brown (except A) with hematoxylin counterstain. Original magnification 200x.
doi:10.1371/journal.pone.0100449.g003
Cthrc1 standards were prepared from purified Cthrc1 with a 7xHis tag fused to the N terminus and expressed in CHO-K1 cells. For analysis of plasma samples for Cthrc1 levels, ELISA plates (MAXISORB, Nunc) were coated at 4°C overnight with 100 µl of anti-Cthrc1 13E09 at 1.8 µg/ml in carbonate buffer (pH = 9.6). Plates were washed four times between all incubations with 400 µl per well of PBS-T containing 0.1% BSA. Wells were blocked with 400 µl of PBS-T containing 0.1% BSA for 1 hour at room temperature on a plate shaker. Samples of 100 µl of undiluted plasma were incubated for 2 hours at room temperature, followed by incubation with biotinylated anti-Cthrc1 10G07 used at 0.5 µg/ml for 60 min. Streptavidin-HRP (Vector Laboratories) was used at 1:1000 dilution followed by the colorimetric reaction with TMB substrate (TMB PLUS LIQUID, Amresco). Optical densities were read at 450 nm with a plate reader (Apollo LB913, Berthold Technologies). The analytical sensitivity of the assay was determined to be 75 pg/ml by calculating the mean ± 3 standard deviations for 16 replicates of the assay diluent. The lower limit of detection of the assay is 160 pg/ml.

Immunohistochemistry, immunoblotting and cell culture

Rabbit monoclonal anti-Cthrc1 clone Vli-55 (www.mmcri.org/antibody) was used for Western blotting and immunohistochemistry on paraffin-embedded, formalin-fixed tissues at 20 ng/ml following antigen retrieval with citrate buffer (0.1 M, pH = 6.0, 10 min in a steamer). This antibody had been previously characterized. It shows no immunoreactivity in any tissue of Cthrc1 null mice [14]. Subsequent steps of the immunostaining procedure were executed as previously published [14]. For immunostaining on tissues containing melanin-expressing cells a red color reaction product was chosen using a kit (VECTASTAIN ABC alkaline phosphatase, VECTOR Red Alkaline Phosphatase Substrate, Vector Laboratories). None of the mouse monoclonal antibodies were suitable for immunohistochemistry on paraffin sections. Immunoblotting was performed on cell lysates (CL) and conditioned media (CM) of HEK293T cells (293) and CHO-K1 cells (CHO) transduced with rat or human Cthrc1 expressing adenovirus as described [14]. Cthrc1 monoclonal antibodies were used at 10 ng/ml.

Statistical Analyses

Data were analyzed using the R programming language. Univariate association tests were performed using t-tests for continuous variables and using chi-squared tests for categorical variables. Cthrc1 levels were set to zero if below the detection limit. Another set of univariate analyses were performed in which a dichotomized version of Cthrc1 (either detectable or >0 or not detectable) was associated with patient characteristics either using a t-test or a chi-squared test.

For association of Cthrc1 levels with clinical diagnoses, because of the non-normal distribution of Cthrc1 levels, a non-parametric Wilcoxon rank sum test was used to measure the association between Cthrc1 levels and particular diagnoses. For Maine Medical Center inpatient data, EPIC electronic medical record system codes were extracted from the patient’s history and for each ICD-9 (International Classification of Disease) code, a patient was listed as having or not having that diagnosis. Then a Wilcoxon test was used to find the association between Cthrc1 levels for ICD-9 codes with at least 5 patients. Another set of analyses were run in which ICD-9 codes were grouped at the level before the decimal point. For the outpatient samples from the primary care facility where EPIC codes were not available, the doctor’s notes were parsed and searched for common medical conditions taking into account misspellings or common synonyms (diabetes, type II diabetes, T2D, etc.). Again, for each condition, patients were divided into categories with and without the condition, and a Wilcoxon test was used to test association with Cthrc1 levels.

Results

Cthrc1 expression in remodeling tissues of adult mice

Increased Cthrc1 expression has been reported in many cancer cells using a variety of commercially available polyclonal antibodies, however, most of them lack rigorous characterization with respect to specificity in immunohistochemistry applications. We used tissues from wildtype and Cthrc1 null mice to evaluate specificity of Cthrc1 immunohistochemistry. Among the many polyclonal and monoclonal anti-Cthrc1 antibodies generated in our laboratory, only clone Vli-55 was found to be specific for immunohistochemistry applications (Fig. 2). Wildtype mice but not Cthrc1 null mice had Cthrc1 protein localization in stromal cells and myofibroblasts of remodeling tissues, such as the heart and arteries in response to continuous angiotensin II infusion (Fig. 2A-D). These findings are consistent with our original discovery of Cthrc1 by in situ hybridization in the remodeling adventitia of balloon injured rat arteries [1]. Similarly, skin incisional wounds (Fig. 2E) and ischemic muscle injury induced by femoral artery ligation (Fig. 2F) showed Cthrc1 protein in interstitial cells and activated fibroblasts but no expression was detectable in uninjured tissues (not shown). In a model of rheumatoid arthritis induced by anti-collagen antibody injection [16], Cthrc1 protein was localized in activated synovial fibroblasts (Fig. 2G). In a spontaneously occurring testicular germ cell tumor, Cthrc1 was detected in outer mural cells of remodelling small vessels (Fig. 2H). In pancreatic ductal carcinoma, Cthrc1 was localized in some stromal cells surrounding the cancer cells (Fig. 2I). In none of the specimens examined did we ever find Cthrc1 in the parenchymal cells or the tumor cells themselves.

Cthrc1 in stromal cells of human cancers

Microarray analyses have identified Cthrc1 as a gene overexpressed in many cancers [2,3] [4] [5,6,7,8,9,10,11,12] with reports of Cthrc1 localization in cancer cells as determined by immunohistochemistry. It does not appear that the specificity of any commercial antibody was verified using negative control tissues from Cthrc1 null species. Our inability to detect Cthrc1 in the parenchyma of tissues prompted us to investigate Cthrc1 expression in various human cancers by immunohistochemistry.
using rabbit monoclonal anti-Cthrc1 Vli-55. We were unable to detect Cthrc1 expression in any of the cancer cells themselves, but invariably observed Cthrc1 expression in stromal cells within the tumor or surrounding tumor cells (Fig. 3A-H). Occasionally white adipocytes adjacent to the tumor also expressed Cthrc1 (Fig. 3I).

Circulating levels of Cthrc1

We recently reported that Cthrc1 is a circulating factor detectable qualitatively in plasma of healthy human subjects [14]. Here we established a sensitive sandwich ELISA for quantification of Cthrc1 levels in plasma. Because hitherto nothing is known about Cthrc1 blood levels, we sought to determine Cthrc1 levels in healthy human subjects initially only with respect to gender and age. Furthermore, we wanted to know whether any conditions or diseases are associated with altered Cthrc1 levels.

In most healthy human subjects Cthrc1 levels were close to the lower limit of detection of the assay (160 pg/mL) with very few exceptions. It turns out, that all healthy subjects with elevated Cthrc1 levels shared the trait of red hair and fair skin that tans poorly (Fig. 4). It is well established that individuals with red hair and/or poorly tanning skin are carriers of variants of the melanocyte-stimulating hormone receptor gene (MC1R) [17,18]. The Cthrc1 levels varied across different sites. Higher Cthrc1 levels were seen at the outpatient location (median concentration of 41.9 ng/mL as opposed to 12.5 ng/mL at MMC) potentially affected by the time to processing and type of anticoagulant used (see details in Methods). The normal controls had a high average concentration, but this was accounted for by the disproportionate overrepresentation of red haired individuals (Fig. 4). Cthrc1 plasma levels for healthy individuals excluding this sub-population were below the detection limit of the assay. For this reason, comparisons in Cthrc1 levels need to be made within and not between patient data sets.

Table 2 shows the association between patient characteristics and levels of Cthrc1 (either detectable or not detectable). We show a strong association between high Cthrc1 levels and red hair color (p = 1.6 x 10^-5). In addition we show an association between increased BMI and high levels of Cthrc1 in the outpatient group (p = 5.93 x 10^-4), however, this association was not observed in either the inpatient or healthy controls group. Gender did not show an association with Cthrc1 levels.

Tables 3 and 4 show the association between clinical diagnostic categories and high Cthrc1 levels in the MMC inpatient group for minor and major ICD-9 groupings, respectively. These groupings define whether a patient had a given diagnosis, defined by ICD-9 code in EPIC, recorded in their electronic medical record. The total number of different ICD-9 categories within our populations was 134 and 130 for minor and major categories, respectively. Categories shown have a p-value < 0.05 and the estimated false positive rate was controlled for using the Bonferroni correction.
Table 2. Univariate association of demographic variables with Cthrc1.

|                          | MMC Inpatients (N = 505) | Primary Care Outpatients (N = 792) | Healthy Controls (N = 40) |
|--------------------------|--------------------------|------------------------------------|--------------------------|
|                          | Cthrc1 > 0 | N.D. | Cthrc1 > 0 | N.D. | Cthrc1 > 0 | N.D. |
| Gender                   |            |      |            |      |            |      |
| Male                     |           | 80 (49.1%) | 119 (50.9%) | 288 (44.6%) | 61 (46.6%) | 3 (42.9%) | 10 (31.3%) |
| Female                   |           | 83 (50.9%) | 115 (49.1%) | 358 (55.4%) | 70 (53.4%) | 4 (57.1%) | 22 (68.8%) |
| Age                      |           | 48.6 | 50.1 (0.29) | 60.0 | 58.7 (0.44) | 38.6 | 39.4 (0.883) |
| Height (inches)          |           | 66.5 | 66.3 (0.79) | - | - | 68.4 | 66.1 (0.158) |
| Weight (pounds)          |           | 190.7 | 196.4 (0.36) | - | - | 165.0 | 148.3 (0.341) |
| Body mass index          |           | 31.0 | 31.8 (0.59) | 30.9 | 28.6 (5.93e-4) | 26.8 | 23.7 (0.209) |
| Hair Color               |           | - | - | - | 6 (75%) | 0 (0%) |
|                          |           | - | - | - | 2 (25%) | 30 (100%) |

For categorical variables, percentage is given for each group (Cthrc1 > 0 or not detectable, N.D.) and p-value is from the Fisher’s exact test. For continuous variables, the mean value for each group is given with the p-value from a t-test given in parentheses. Significant associations are shaded in grey.

doi:10.1371/journal.pone.0100449.t002

Discussion

The present study had several purposes. They included i) identification of cells expressing Cthrc1 in cancers and normal tissues, ii) determination of circulating levels of Cthrc1 and identify conditions associated with altered Cthrc1 levels, iii) characterization of Cthrc1 plasma levels as a potential biomarker, and iv) identification of cell types contributing to circulating levels of Cthrc1 expression in the liver, indicating that expression by hepatocytes will result in circulating Cthrc1 levels. With Cthrc1 expression in wound healing and cancers originating from activated stromal cells we wanted to determine whether Cthrc1 expressed by these cells can account for circulating levels with potential systemic effects. Because Pdgfrb is expressed in mesenchymal and stromal cells [20], we used a transgenic mouse expressing Cre recombinase under control of the Pdgfrb promoter [15] to overexpress Cre inducible human Cthrc1. This allowed us to determine plasma levels specifically for human Cthrc1 because our ELISA for Cthrc1 does not detect murine Cthrc1. In bi-transgenic Tg(CagGfp-hCthrc1)19/ Tg(Pdgfrb-Cre)2371 mice Cthrc1 was overexpressed in skeletal muscle (Fig. 5A), small vessels of adipose tissue and liver (Fig. 5B, C) as well as vascular smooth muscle (Fig. 5D). The transgene was also expressed in outer mural cells (Fig. 5E) similar to endogenous Cthrc1 in remodeling vessels (Fig. 2C and H). Analysis of Cthrc1 plasma levels by ELISA, however, revealed that transgenic overexpression did not increase circulating Cthrc1 levels as they remained below the detection limit in both transgenic and wildtype mice (data not shown). This suggests that Cthrc1 expressed in these tissues may not be contributing to circulating levels and instead is likely being act locally.

Recently we reported expression of Cthrc1 in the anterior pituitary of rats and pigs [14]. Here we obtained human pituitary glands and localized Cthrc1 in them by immunohistochemistry. Localized accumulations and small lacunae of Cthrc1 immunoreactivity were found throughout the anterior lobe (Fig. 6). In most cases these accumulations were surrounded by chromophobe cells but they were not encapsulated. Cytoplasmic immunoreactivity indicating expression by cells was clearly evident (Fig. 6A). These findings clearly identify Cthrc1 as a pituitary factor in humans.

Potential sources of circulating Cthrc1

We previously described transgenic mice overexpressing myctagged Cthrc1 under control of the CMV promoter and observed circulating levels of Cthrc1 in plasma that were readily detectable by immunoblotting with HRP-conjugated anti-Cthrc1 antibodies [14]. In these mice, Cthrc1 was predominantly ectopically expressed in the liver, indicating that expression by hepatocytes will result in circulating Cthrc1 levels. With Cthrc1 expression in wound healing and cancers originating from activated stromal cells we wanted to determine whether Cthrc1 expressed by these cells can account for circulating levels with potential systemic effects. Because Pdgfrb is expressed in mesenchymal and stromal cells [20], we used a transgenic mouse expressing Cre recombinase under control of the Pdgfrb promoter [15] to overexpress Cre inducible human Cthrc1. This allowed us to determine plasma levels specifically for human Cthrc1 because our ELISA for Cthrc1 does not detect murine Cthrc1. In bi-transgenic Tg(CagGfp-hCthrc1)19/ Tg(Pdgfrb-Cre)2371 mice Cthrc1 was overexpressed in skeletal muscle (Fig. 5A), small vessels of adipose tissue and liver (Fig. 5B, C) as well as vascular smooth muscle (Fig. 5D). The transgene was also expressed in outer mural cells (Fig. 5E) similar to endogenous Cthrc1 in remodeling vessels (Fig. 2C and H). Analysis of Cthrc1 plasma levels by ELISA, however, revealed that transgenic overexpression did not increase circulating Cthrc1 levels as they remained below the detection limit in both transgenic and wildtype mice (data not shown). This suggests that Cthrc1 expressed in these tissues may not be contributing to circulating levels and instead is likely being act locally.

Recently we reported expression of Cthrc1 in the anterior pituitary of rats and pigs [14]. Here we obtained human pituitary glands and localized Cthrc1 in them by immunohistochemistry. Localized accumulations and small lacunae of Cthrc1 immunoreactivity were found throughout the anterior lobe (Fig. 6). In most cases these accumulations were surrounded by chromophobe cells but they were not encapsulated. Cytoplasmic immunoreactivity indicating expression by cells was clearly evident (Fig. 6A). These findings clearly identify Cthrc1 as a pituitary factor in humans.
### Table 3. Univariate association of EPIC diagnostic codes (ICD-9 codes) with Cthrc1 for MMC inpatient data.

| ICD-9   | Diagnosis                                                      | With Diagnosis | Mean without Diagnosis | Mean with Diagnosis | Test Statistic | p-value | FDR   |
|---------|----------------------------------------------------------------|----------------|------------------------|---------------------|---------------|---------|-------|
| 205.00  | acute myeloid leukemia                                        | 7              | 14.21                  | 29.06               | 1799.50       | 0.0022  | 0.1478|
| 276.69  | volume overload                                               | 6              | 14.54                  | 33.30               | 1545.00       | 0.0027  | 0.1478|
| 780.60  | fever                                                         | 26             | 12.95                  | 13.48               | 4673.50       | 0.0033  | 0.1478|
| 112.0   | thrush                                                        | 9              | 14.04                  | 25.17               | 1912.00       | 0.0044  | 0.1478|
| 285.9   | anemia                                                        | 68             | 12.02                  | 33.96               | 9115.50       | 0.0083  | 0.1968|
| 285.21  | anemia in end-stage renal disease or chronic kidney disease   | 9              | 14.78                  | 43.49               | 1823.50       | 0.0088  | 0.1968|
| 780.57  | sleep apnea                                                   | 13             | 12.14                  | 70.76               | 2325.50       | 0.0115  | 0.2211|
| 250.60  | diabetic neuropathy or unspecified type diabetes mellitus with neurological manifestations | 15             | 14.13                  | 60.12               | 2805.00       | 0.0213  | 0.3566|
| 599.0   | urinary tract infection                                       | 19             | 12.29                  | 70.35               | 2978.50       | 0.0270  | 0.4023|
| 250.01  | diabetes mellitus, type 1                                     | 6              | 14.87                  | 18.91               | 1462.00       | 0.0352  | 0.4268|
| 008.45  | clostridium difficile colitis                                  | 7              | 10.34                  | 41.99               | 1297.00       | 0.0373  | 0.4268|
| 790.4   | transaminitis                                                 | 10             | 12.38                  | 78.87               | 1668.00       | 0.0382  | 0.4268|

A Wilcoxon rank sum test is used to compare the rank of Cthrc1 levels for patients with and without a given ICD-9 code. Only codes with at least 5 patient instances are included in the analysis. Included results are the mean in each group, the Wilcoxon test statistic, the p-value, and the adjusted p-value (the estimated false discovery rate, FDR). Results presented have a p-value < 0.05 and the estimated FDR is shown. ICD-9 codes and a representative diagnosis are shown.

doi:10.1371/journal.pone.0100449.t003

### Table 4. Univariate association of EPIC diagnostic codes (ICD-9 codes) with Cthrc1 for MMC inpatient data, summarized at the major grouping (before the decimal point).

| ICD-9   | Diagnosis                                                      | With Diagnosis | Mean without Diagnosis | Mean with Diagnosis | Test Statistic | p-value | FDR   |
|---------|----------------------------------------------------------------|----------------|------------------------|---------------------|---------------|---------|-------|
| 998     | wound infection after surgery                                  | 6              | 13.54                  | 64.09               | 1560.50       | 0.0021  | 0.2788|
| 112     | yeast infection                                               | 16             | 16.20                  | 25.89               | 2918.50       | 0.0092  | 0.5470|
| 90      | healthcare maintenance                                         | 39             | 14.61                  | 24.86               | 5189.00       | 0.0226  | 0.5470|
| 285     | anemia                                                        | 81             | 12.56                  | 17.76               | 9878.50       | 0.0280  | 0.5470|
| 327     | obstructive sleep apnea                                        | 20             | 14.43                  | 33.41               | 3052.00       | 0.0296  | 0.5470|
| 599     | urinary tract infection                                        | 26             | 13.16                  | 55.53               | 3735.00       | 0.0320  | 0.5470|
| 8       | clostridium difficile colitis                                  | 7              | 10.34                  | 41.99               | 1297.00       | 0.0373  | 0.5470|
| 707     | ulcer                                                         | 19             | 12.04                  | 53.32               | 3350.00       | 0.0416  | 0.5470|
| 799     | hypoxia                                                       | 17             | 15.34                  | 37.08               | 2330.50       | 0.0498  | 0.5530|

A Wilcoxon rank sum test is used to compare the rank of Cthrc1 levels for patients with and without a given ICD-9 code. Only codes with at least 5 patient instances are included in the analysis. Included results are the mean in each group, the Wilcoxon test statistic, the p-value, and the adjusted p-value (the estimated false discovery rate). Results presented have a p-value < 0.05 and the estimated FDR is shown. ICD-9 major codes and a representative diagnosis are shown.

doi:10.1371/journal.pone.0100449.t004
Cthrc1. Using rigorously validated monoclonal Cthrc1 antibodies we demonstrate that in all of our cases Cthrc1 expression in human cancers originates from activated stromal cells, not the tumor cells themselves. As we have shown earlier [1] and recently confirmed by Spector et al [13], Cthrc1 is characteristically expressed by the activated fibroblast in remodeling, non-cancerous tissues. In novel Cre-inducible transgenic mice that overexpress Cthrc1 in cells where the \( Pdgfrb \) promoter had previously been activated, we found no elevation of circulating Cthrc1 levels. This suggests that expression of Cthrc1 by a variety of cell types including vascular cells, skeletal muscle cells and fibroblasts, is not likely to contribute to circulating Cthrc1 levels. Instead, Cthrc1 expressed by these cells may be acting locally in a paracrine or autocrine manner. This idea is supported by the fact that we did not observe elevated Cthrc1 levels in patients with solid cancers. With regards to the cancer patient population one limitation is that our analysis focused on general patients and not specifically oncologic patients, and thus we did not have high power to detect association with many cancers. In the major groupings analysis, the group that contains AML (acute myelogenous leukemia 205.00 and chronic myeloid leukemia 205.10) just barely missed the cutoff (9 cases, \( p = 0.0523 \), FDR = 0.55) but was generally consistent with the minor groupings analysis. Future work with a focus on oncology patients is required for a more in-depth investigation of Cthrc1 levels in cancer patients.

A common theme emerged with the detection of elevated Cthrc1 levels in patients suffering from conditions that have an inflammatory or infectious component, e.g. fever, yeast and urinary tract infections, thrush, etc., and even diabetes can be included in this category [19]. In this context it should be mentioned that the promoter region of Cthrc1 contains a putative NF-\( \kappa \)B binding site located within 300 base pairs upstream of the transcriptional start site, however, its function has until now not been examined. Combined these findings suggest a link between Cthrc1 levels and inflammation.

Examining Cthrc1 plasma levels in healthy human subjects we made the unexpected discovery that all subjects with red hair had elevated Cthrc1 levels, some with levels several hundred fold higher than subjects with hair color other than red. Valverde et al. [17] have demonstrated previously that variants of the MC1R gene are responsible for pigmentation and red hair color in humans. Signaling via MC1R is responsible for the production of

| Diagnosis          | With Diagnosis | Mean without Diagnosis | Mean with Diagnosis | Test Statistic | p-value  | FDR      |
|--------------------|----------------|------------------------|---------------------|---------------|----------|----------|
| diabetes           | 264            | 70.47                  | 123.77              | 79613         | 0.000029 | 0.001659 |
| type 2 diabetes    | 184            | 75.77                  | 129.85              | 65115         | 0.000035 | 0.001659 |
| hypertension       | 417            | 73.46                  | 101.63              | 86731.5       | 0.000088 | 0.002829 |
| osteoporosis       | 40             | 87.52                  | 108.04              | 17576.5       | 0.019677 | 0.398531 |
| spinal stenosis    | 25             | 85.38                  | 184.77              | 11645.5       | 0.020757 | 0.398531 |
| hyperlipidemia     | 313            | 81.53                  | 99.02               | 78462         | 0.028095 | 0.430823 |
| hyperglycemia      | 23             | 88.30                  | 97.61               | 10591.5       | 0.034756 | 0.430823 |
| erectile dysfunction| 63             | 86.57                  | 111.34              | 25542         | 0.036680 | 0.430823 |
| hyperthyroidism    | 6              | 88.23                  | 132.99              | 3267.5        | 0.040390 | 0.430823 |
| obesity            | 116            | 84.13                  | 113.95              | 42074         | 0.046534 | 0.446724 |

A Wilcoxon rank sum test is used to compare the rank of Cthrc1 levels for patients with and without a phrase found in their history. Only phrases with at least 5 patient instances are included in the analysis. Included results are the mean in each group, the Wilcoxon test statistic, the p-value, and the adjusted p-value (the estimated false discovery rate). Results shown have a p-value <0.05 and the estimated FDR is shown.

doi:10.1371/journal.pone.0100449.t005

**Figure 5. Mouse transgenic model of Cthrc1 overexpression.** Cthrc1 protein was assessed by immunohistochemistry in bi-transgenic Tg(CagGfp-hCthrc1)\(^{Vli}\) Tg(Pdgfrb-Cre)\(^{35Vli}\) mice. (A) Skeletal muscle, (B) capillaries in brown adipose tissue, (C) hepatic endothelium, (D) vascular smooth muscle in the kidney, and (E) mural cells of venules expressed Cthrc1. (F) As a control, no Cthrc1 expression is detectable in wildtype skeletal muscle. Cthrc1 immunoreactivity in brown with hematoxylin counterstain. Original magnification 200x (A-D), 400x (E), and 100x (F).

doi:10.1371/journal.pone.0100449.g005
Cthrc1 in Health and Disease

Figure 6. Cthrc1 localizes to the pituitary gland. Immunolocalization of Cthrc1 in human pituitary glands identifies cells expressing Cthrc1 in the anterior lobe (A, arrow). (B, C) Accumulations of colloid-like material contain Cthrc1 immunoreactivity. (D) Absence of non-specific staining is observed with an irrelevant monoclonal antibody. (E, F) Cells surrounding Cthrc1 immunoreactivity are of the chromophobe type. Original magnification 200x (A-C), 100x (D), 400x (E, F).

doi:10.1371/journal.pone.0100449.g006

References

1. Pyapay P, Hensel M, Wang Q, Lepore N, Belden J, et al. (2005) Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 96: 261–268.
2. Tang L, Dai DL, Su M, Martinka M, Li G, et al. (2006) Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 12: 3716–3722.
3. Zhang Q, Li G (2012) Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS One 7: e45037.
4. Chen YL, Wang TH, Hsu HC, Yuan RH, Jeung YM (2013) Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLoS One 8: e70324.
5. Liu G, Sengupta PK, Jamal B, Yang HY, Bouchie MP, et al. (2013) N-glycosylation induces the CTHRC1 protein and drives oral cancer cell migration. J Biol Chem 288: 20217–20227.
6. Kim JH, Baek TH, Yun HS, Kim KH, Jeong SH, et al. (2013) Collagen Triple Helix Repeat Containing-1 (CTHRC1) Expression in Invasive Ductal Carcinoma of the Breast: The Impact on Prognosis and Correlation to Clinicopathologic Features. Pathol Oncol Res 19: 731–737.
7. Kharainshvili G, Czukowa M, Bouchalova K, Mgebrishvili G, Kolar Z, et al. (2011) Collagen triple helix repeat containing 1 protein, peristin and versican in primary and metastatic breast cancer: an immunohistochemical study. J Clin Pathol 64: 977–982.

In summary, we report here that Cthrc1 is a marker for activated stromal cells and Cthrc1 expression was not detectable in the cancer cells. Furthermore, Cthrc1 is expressed in the human pituitary predominantly in the anterior lobe. Circulating levels in most healthy subjects are below 1 ng/ml but all subjects with red hair studied here had vastly higher levels. Cthrc1 plasma levels were also significantly elevated during pregnancy, in diabetes, in inflammatory and infectious conditions, acute myeloid leukemia but not solid cancers.

Acknowledgments

This study was supported by Maine Medical Center's BioBank, a core facility of the institution, which was critical to the conduct of this project. We would like to acknowledge the assistance and help by the staff of Martin's Point Health Care (Portland, ME) who made collection of plasma samples from outpatients possible. The technical assistance of Nicole Perreault was greatly appreciated.

Author Contributions

Conceived and designed the experiments: IFE VL. Performed the experiments: JPS QW VL. Analyzed the data: CD IFE AP VL. Contributed reagents/materials/analysis tools: CD AP VL. Performed the experiments: CD AP VL. Contributed to the writing of the manuscript: CD AP VL.
8. Park EH, Kim S, Jo JY, Kim SJ, Hwang Y, et al. (2013) Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis 34: 694–702.

9. Tan F, Liu F, Liu H, Hu Y, Liu D, et al. (2013) CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: a new predictor for prognosis. Med Oncol 30: 473.

10. Palma M, Lopez I, Garcia M, de Roja N, Ruiz T, et al. (2012) Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer. BMC Clin Pathol 12: 2.

11. Wang P, Wang YC, Chen XY, Shen ZY, Cao H, et al. (2012) CTHRC1 is upregulated by promoter demethylation and transforming growth factor-beta1 and may be associated with metastasis in human gastric cancer. Cancer Sci 103: 1327–1333.

12. Wang L, Xiang YN, Zhang YH, Tu YT, Chen HX (2011) Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma. Br J Dermatol 164: 155–140.

13. Spector I, Zilberstein Y, Lavy A, Genin O, Barzilai-Tutsch H, et al. (2013) The involvement of collagen triple helix repeat containing 1 in muscular dystrophies. Am J Pathol 182: 905–916.

14. Stohn JP, Perreault NG, Wang Q, Liaw L, Lindhor V (2012) Cthrc1, a novel circulating hormone regulating metabolism. PLoS One 7: e47142.

15. Cuttler AS, Leclair RJ, Stohn JP, Wang Q, Sorensen CM, et al. (2011) Characterization of pdgfrb-cre transgenic mice reveals reduction of ROSA26 reporter activity in remodeling arteries. Genesis.

16. Glant TT, Szanto S, Vegvari A, Szabo Z, Kis-Toth K, et al. (2008) Two loci on chromosome 15 control experimentally induced arthritis through the differential regulation of IL-6 and lymphocyte proliferation. J Immunol 181: 1307–1314.

17. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ (1999) Variants of the melanocortin 1 receptor gene are associated with red hair and fair skin in humans. Nat Genet 11: 328–330.

18. Healy E, Jordan SA, Budd PS, Suffolk R, Rees JL, et al. (2001) Functional variation of MC1R alleles from red-haired individuals. Hum Mol Genet 10: 2397–2402.

19. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11: 98–107.

20. Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, et al. (2013) PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia 15: 294–217.

21. Rees JL (2000) The melanocortin 1 receptor (MC1R): more than just red hair. Pigment Cell Res 13: 135–140.

22. Harding RM, Healy E, Ray AJ, Ellis NS, Flanagan N, et al. (2000) Evidence for variable selective pressures at MC1R. Am J Hum Genet 66: 1351–1361.

23. Healy E, Todd C, Jackson I, Birch-Machin M, Rees JL (1999) Skin type, melanoma, and melanocortin 1 receptor variants. J Invest Dermatol 112: 512–513.

24. Williams PF, Olsen CM, Hayward NK, Whiteman DC (2011) Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 129: 1730–1740.

25. Kimura H, Kwan KM, Zhang Z, Deng JM, Darnay BG, et al. (2008) Cthrc1 is a positive regulator of osteoblastic bone formation. PLoS ONE 3: e13174.

26. Bohm M, Grassel S (2012) Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research. Endocr Rev 33: 623–631.